TAU targets drug-resistant ovarian tumors with nanotechnology
Ovarian cancer accounts for more deaths of American women than any other cancer of the female reproductive system. According to the American Cancer Society, one in 72 American women will be diagnosed with ovarian cancer, and one in 100 will ultimately die of the condition.
Now Prof. Dan Peer of Tel Aviv University‘s Department of Cell Research and Immunology has proposed a new strategy to tackle an aggressive subtype of ovarian cancer using a new nanoscale drug-delivery system designed to target specific cancer cells. He and his team — Keren Cohen and Rafi Emmanuel from Peer’s Laboratory of Nanomedicine and Einat Kisin-Finfer and Doron Shabbat, from TAU’s Department of Chemistry — have devised a cluster of nanoparticles called gagomers, made of fats and coated with a kind of polysugar. When filled with chemotherapy drugs, these clusters accumulate in tumors, producing dramatically therapeutic benefits.
The objective of Peer’s research is two-fold: to provide a specific target for anti-cancer drugs to increase their therapeutic benefits, and to reduce the toxic side effects of anti-cancer therapies. The study was published in February in the journal ACS Nano.
Why chemotherapy fails
According to Prof. Peer, traditional courses of chemotherapy are not an effective line of attack. Chemotherapy’s failing lies in the inability of the medicine to be absorbed and maintained within the tumor cell long enough to destroy it. In most cases, the chemotherapy drug is almost immediately ejected by the cancer cell, severely damaging the healthy organs that surround it, leaving the tumor cell intact.
But with their new therapy, Peer and his colleagues saw a 25-fold increase in tumor-accumulated medication and a dramatic dip in toxic accumulation in healthy organs. Tested on laboratory mice, the gagomer mechanism effects a change in drug-resistant tumor cells. Receptors on tumor cells recognize the sugar that encases the gagomer, allowing the binding gagomer to slowly release tiny particles of chemotherapy into the cancerous cell. As more and more drugs accumulate within the tumor cell, the cancer cells begin to die off within 24-48 hours.
“Tumors become resistant very quickly. Following the first, second, and third courses of chemotherapy, the tumors start pumping drugs out of the cells as a survival mechanism,” said Prof. Peer. “Most patients with tumor cells beyond the ovaries relapse and ultimately die due to the development of drug resistance. We wanted to create a safe drug-delivery system, which wouldn’t harm the body’s immune system or organs.”
The Latest on: Ovarian cancer
[google_news title=”” keyword=”Ovarian cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Ovarian cancer
- Compugen COM701 in dual/triple combo shows promise in ovarian cancer patients in trialon December 6, 2022 at 5:42 am
Compugen (CGEN) said its drug COM701 in dual and triple combination with Bristol-Myers Squibb's (BMY) Opdivo (nivolumab) ± BMS-986207 (anti-TIGIT) showed preliminary ...
- I Thought It Was Cancer: Mom Who Gave Birth at 49 on Her Miracle Babyon December 6, 2022 at 5:00 am
"I went to the doctor expecting a menopause diagnosis and just two hours later, I was having an emergency ultrasound as they thought it might be cancer." ...
- Know the Warning Signs of Cancer, as Kirstie Alley Dies of the Diseaseon December 6, 2022 at 4:15 am
There's more than 100 types of cancer and many are becoming more treatable thanks to advances in technology and medicine.
- Doctors dismissed my symptoms — until I was diagnosed with rare ovarian canceron December 2, 2022 at 4:14 pm
“I thought my pain would finally go away.” A week later, Sanders received news that uprooted her world: she had a rare and aggressive ovarian cancer and needed immediate treatment. “I am 1 of 500 ...
- 21-year-old's pain was dismissed by doctors for years. She had a rare ovarian canceron December 2, 2022 at 11:58 am
Sharp abdominal pain struck Jessie Sanders' body. For almost two weeks in November 2021, she couldn't eat, work out or move. All she did was lie in bed.
- Woman, 21, had severe abdominal pain for years. Doctors dismissed it. It was ovarian canceron December 2, 2022 at 9:58 am
"I knew there’s something else wrong with my body,” Sanders said she would tell doctors, who told her the pain was just period cramps and hormones.
- Machine learning fusion prototype could potentially help detect ovarian canceron November 30, 2022 at 1:21 pm
The study is the first to use ultrasound to improve the machine learning performance of photoacoustic tomography reconstruction for cancer diagnosis.
- FDA Approves New Treatment for Ovarian Canceron November 29, 2022 at 2:11 pm
The U.S. Food and Drug Administration (FDA) has approved a new drug to treat certain types of ovarian cancer in patients who don’t get optimal outcomes from other medicines.
- Researchers highlight the importance of localizing BRCA gene mutations for better ovarian cancer treatmenton November 28, 2022 at 9:17 am
Mutations of BRCA1 and BRCA2 genes, which are inherited by 1 in 400 and 1 in 800 people respectively, significantly increase the risk of certain cancers such as ovarian, breast, pancreatic and ...
via Bing News